{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:09:12Z","timestamp":1781089752384,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center","doi-asserted-by":"publisher","award":["SMO126004"],"award-info":[{"award-number":["SMO126004"]}],"id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HC23C0249"],"award-info":[{"award-number":["HC23C0249"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jns.2026.125909","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:19:06Z","timestamp":1775578746000},"page":"125909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study"],"prefix":"10.1016","volume":"486","author":[{"given":"Soonwook","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwoo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hak","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125909_bb0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.125909_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.125909_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.125909_bb0020","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1111\/ene.14901","article-title":"Very late onset neuromyelitis optica spectrum disorders","volume":"28","author":"Nakahara","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.125909_bb0025","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jns.2026.125909_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1458556","article-title":"Effects of early intervention in neuromyelitis optica spectrum disorder patients with seropositive AQP4 antibodies","volume":"15","author":"Xue","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.125909_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168638","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"22","author":"Chan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2026.125909_bb0040","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2026.125909_bb0045","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/jnnp-2024-333644","article-title":"Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study","volume":"95","author":"Kim","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.125909_bb0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jamainternmed.2015.7110","article-title":"Korean National Health Insurance database","volume":"176","author":"Shin","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jns.2026.125909_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.125909_bb0060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/13524585241237093","article-title":"Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea","volume":"30","author":"Kwon","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2026.125909_bb0065","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/jnnp-2022-329389","article-title":"Risk of Parkinson\u2019s disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea","volume":"93","author":"Kwon","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.125909_bb0070","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jns.2026.125909_bb0075","first-page":"165","article-title":"Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis","volume":"97","author":"Gavoille","year":"2026","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.125909_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M16-0758","article-title":"Effectiveness of screening colonoscopy to prevent colorectal cancer among medicare beneficiaries aged 70 to 79 years: a prospective observational study","volume":"166","author":"Garc\u00eda-Alb\u00e9niz","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jns.2026.125909_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13054-023-04328-6","article-title":"Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data","volume":"27","author":"Massol","year":"2023","journal-title":"Crit. Care"},{"key":"10.1016\/j.jns.2026.125909_bb0090","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.jns.2026.125909_bb0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2026.125909_bb0100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2026.125909_bb0105","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/epi.13769","article-title":"Anxiety and depressive disorders in people with epilepsy: a meta-analysis","volume":"58","author":"Scott","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2026.125909_bb0110","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jns.2026.125909_bb0115","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ene.15239","article-title":"Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies","volume":"29","author":"Wang","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.125909_bb0120","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder","volume":"29","author":"Huang","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.125909_bb0125","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001179","article-title":"Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience","volume":"9","author":"Kim","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jns.2026.125909_bb0130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/CPJ.0b013e3182a78f82","article-title":"Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder","volume":"3","author":"Flanagan","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.jns.2026.125909_bb0135","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.15458","article-title":"Increased risk of thiopurine-related adverse events in elderly patients with IBD","volume":"50","author":"Calafat","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2026.125909_bb0140","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40744-023-00595-5","article-title":"Association between Mycophenolate mofetil use and subsequent infections among hospitalized patients with systemic lupus erythematosus: a nested case-control study","volume":"10","author":"Guo","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jns.2026.125909_bb0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000509893","article-title":"Severe infections following rituximab treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Li","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.jns.2026.125909_bb0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jns.2026.125909_bb0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.it.2009.04.003","article-title":"Thymic involution and immune reconstitution","volume":"30","author":"Lynch","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jns.2026.125909_bb0160","article-title":"Immunosenescence, aging and successful aging","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.125909_bb0165","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:08:04Z","timestamp":1778702884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S0022510X26001917"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125909","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125909"}}